Mangoceuticals, Inc. (MGRX): who owns it and who trades it
As of Nov 16, 2026, MGRX insiders reported 4 open-market sales worth $174K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alex P. Hamilton (Director), with $152K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Mangoceuticals
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, MGRX insiders reported $0 of open-market purchases and $174K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Eugene M Johnston | CFO | Sale | 3,333 | $1.17 | $3.9K | Form 4 |
| Dec 9, 2025 | Eugene M Johnston | CFO | Sale | 5,000 | $1.20 | $6K | Form 4 |
| Dec 5, 2025 | Eugene M Johnston | CFO | Sale | 10,000 | $1.13 | $11.3K | Form 4 |
| Nov 19, 2025 | Alex P. Hamilton | Director | Sale | 125,000 | $1.22 | $152K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Alex P. Hamilton | Director | – | $152K | Nov 19, 2025 |
| Eugene M Johnston | CFO | – | $21.2K | Dec 15, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MGRX short interest
Low short interest. 0.2% of MGRX shares are sold short: about 1 share in 404. Over the last 12 reports the number of shares short went down 86%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 53,343 MGRX shares were sold short, 0.2% of the shares outstanding, down 41.7% from the report before. At the average daily volume of 369,429 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 53,343 | 0.25% | -42% | 369,429 | 1.0 |
| Oct 15, 2026 | 91,564 | 0.42% | -79% | 739,664 | 1.0 |
| Sep 30, 2026 | 438,786 | 2.03% | -16% | 655,308 | 1.0 |
| Sep 15, 2026 | 521,424 | 2.42% | -18% | 298,483 | 1.8 |
| Aug 31, 2026 | 632,502 | 2.93% | -65% | 861,529 | 1.0 |
| Aug 14, 2026 | 1.81M | 8.40% | -4% | 19.10M | 1.0 |
| Jul 31, 2026 | 1.88M | 11.09% | +805% | 49.41M | 1.0 |
| Jul 15, 2026 | 207,868 | 1.23% | -46% | 627,822 | 1.0 |
| Jun 30, 2026 | 385,972 | 2.27% | +44% | 4.33M | 1.0 |
| Jun 15, 2026 | 268,818 | 1.58% | +16% | 325,680 | 1.0 |
| May 29, 2026 | 231,103 | 1.36% | -39% | 494,880 | 1.0 |
| May 15, 2026 | 380,693 | 2.24% | -16% | 1.11M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Mangoceuticals company events
Mangoceuticals filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 6, 2026.
- Nov 6, 2026AnnouncementOf this Current Report on Form 8-K is incorporated by reference into this Item 5.08, to the extent applicable. Filing
- Oct 9, 2026AgreementMangoceuticals, Inc. entered into a securities purchase agreement with certain investors, pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering, (i) 657,000 shares of common stock, par value $0.0001 per share, of the Company, (ii) common warrants… Filing
- Oct 1, 2026DealTo the extent required by Item 2.01, the information set forth in Item 1.01 above is incorporated by reference into this Item 2.01. Filing
- Aug 21, 2026AgreementEnded an important agreement. Filing
- Aug 4, 2026AnnouncementAs previously disclosed, on February 4, 2026, Mangoceuticals, Inc. received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of the… Filing
- Jul 30, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers. Filing
- Jul 2, 2026AgreementMangoceuticals, Inc. entered into a Subscription Agreement with an accredited investor, pursuant to which the Investor purchased 850,000 shares of restricted common stock from the Company, for $0.32 per share, or a total of $272,000. Filing
- Mar 17, 2026LeadershipUpon the recommendation of the compensation committee of the Board of Directors of Mangoceuticals, Inc., and pursuant to the authority provided to the Board pursuant to the terms of the Company’s 2022 Equity Incentive Plan, as amended and restated, which has previously been approved by the… Filing
- Feb 23, 2026AnnouncementShared information with investors. Filing
- Feb 19, 2026AnnouncementShared information with investors. Filing
- Feb 6, 2026ListingMangoceuticals, Inc. received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of the Company’s common stock had closed below $1.00 per… Filing
- Dec 19, 2025AgreementMangoceuticals, Inc. entered into a securities purchase agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor (a) in a registered direct offering, (A) 1,430,502 shares of common stock, par value $0.0001 per share, of the Company, at an… Filing
- Dec 19, 2025AgreementMango DAT, LLC, a wholly owned subsidiary of Mangoceuticals, Inc. and Cube Operations LLC entered into a Master Services Agreement. Filing
- Dec 10, 2025AgreementMangoceuticals, Inc., borrowed $75,000 from The Tiger Cub Trust, which trust is controlled by the Company’s Chief Executive Officer and Chairman, Jacob D. Cohen, and entered into a Promissory Note with Tiger Cub to evidence such loan. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Mangoceuticals financials
Famous investors that hold MGRX
1 of the 50 well-known investors we track reported holding MGRX in their latest 13F filing. The largest position is Ken Griffin's, worth $80.9K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 189,004 | $80.9K | 0.0% | -44% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MGRX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 6, 2026 | Jacob D. Cohen | 13D/A | 21.5% |
| Oct 6, 2026 | Jacob D. Cohen | 13D/A | 21.5% |
Questions about Mangoceuticals, Inc. (MGRX) stock
Are MGRX insiders buying or selling?
In the last 12 months, MGRX insiders reported no open-market purchases and 4 sales worth $174K. The latest trade was on Dec 15, 2025. See every trade.
What is the short interest in MGRX?
As of Oct 30, 2026, 53,343 MGRX shares were sold short, 0.2% of the shares outstanding, down 41.7% from the report before. At the average daily volume of 369,429 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold MGRX?
1 of the 50 well-known investors we track reported MGRX in their latest 13F filing, including Ken Griffin. The largest position is worth $80.9K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.